Skip to content

Arvinas ARVN Price / sales

Price / sales at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
22.9×+2.1×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
132.1×+102×
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
30.6×+28.9×
Immunome logo
ImmunomeIMNM
616.2×+563×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
883.8×-231×
Arcus Biosciences logo
Arcus BiosciencesRCUS
11.5×+5.6×

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on the most recent quarter.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's price / sales?
Arvinas (ARVN) reported price / sales of 7.6× in Q1 2026.
How has Arvinas's price / sales changed year-over-year?
Arvinas's price / sales increased by 570.6% year-over-year, from 1.1× to 7.6×.
What is the long-term trend for Arvinas's price / sales?
Over 4 years (2020 to 2025), Arvinas's price / sales has grown at a -64.0% compound annual growth rate (CAGR), from 173.4× to 2.9×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.